The cost of antiretroviral drugs and influence on prescribing policies

International Journal of STD and AIDS

Volumn 17, Issue 8, 2006, Pages 499-506

  Jones, Rachael ^a   Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral drugs; Cost; Prescribing policy

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ADEFOVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BMS 045; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANEMIA; BONE INJURY; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG ANTAGONISM; DRUG COST; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPHORIA; GASTROINTESTINAL SYMPTOM; HEALTH CARE POLICY; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; KIDNEY INJURY; LACTIC ACIDOSIS; LIPOATROPHY; LIVER FAILURE; MEDICAL DECISION MAKING; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPTICEMIA; SKIN ALLERGY; STAPHYLOCOCCUS INFECTION; STEVENS JOHNSON SYNDROME; TERATOGENICITY; UNITED KINGDOM;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG COSTS; DRUG UTILIZATION; HIV INFECTIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33747859618     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206778145587     Document Type: Review

References (85)

1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-60
2. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005;6:99-106
3. Keiser O, Taffe P, Zwahlen M, et al. All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004;18:1835-43
4. Beck EJ, Mandalia S, Gaudreault M, et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS 2004;18:2411-18
5. US Renal Data System USRDS 2003 Annual Data Report
6. Javitz HS, Ward MM, Watson JB, et al. Cost of illness of chronic angina. Am J Manage Care 2004;10(11 Suppl):S358-69
7. Mocroft A, Monforte A, Kirk O, et al. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med 2004;5:437-47
8. Keshavjee S. Medicine and money: the ethical transformation of medical practice. Med Educ 2004;38:232-4
9. Asylum seekers: meeting their healthcare needs, British Medical Association, October 2002
10. House of Commons Health Committee. Influence of the Pharmaceutical Industry, Fourth Report of Session 2004-5. 2005 [www.publications.parliament.uk]
11. Fishman PA, Hornbrook MC, Meenan RT, et al. Opportunities and challenges for measuring cost, quality, and clinical effectiveness in health care. Med Care Res Rev 2004;61(3 Suppl):124S-43S
12. The United Kingdom Parliament 18 Nov 2004: Column 1961W
13. O'Neill R. Assessment of safety. In: Peace KE, ed. Biopharmaceutical Statistics for Drug Development. New York, Basel: Marcel Dekker, 1998
14. Kirk O, Lundgren J. Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines. Curr Opin Infect Dis 2004;17:33-7
15. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003;4(Suppl 1):1-41
16. White E, Hunt JR, Casso D, et al. Exposure measurement in cohort studies: the challenges of prospective data collection. Epidemiol Rev 1998;20:43-56
17. Blitz M, Spivack E, Kerpel S, et al. Stevens-Johnson syndrome in an HIV-infected patient. AIDS Reader 1999;9:185-95
18. Clarke S, Harrington P, Condon C, et al. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Int J STD AIDS 2000;11:336-7
19. Lin MS, Dai YS, Pwu RF, et al. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J 2005;35:188-90
20. Powderly W. Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits. Clin Infect Dis 2004;38(Suppl 2):S109-13
21. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005;38:560-5
22. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003
23. ddI, d4T, Hydroxyurea: new pancreatitis warning. AIDS Treat News 1999;1-3
24. Peyriere H, Guillemin V, Lotthe A. Reasons for early abacavir discontinuation in HIV-infected patients. Ann Pharmacother 2003;37:1392-7
25. Moyle G, Sawyer W, Law M. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004;26:92-7
26. Datta D, Moyle G, Mandalia S, et al. Matched case-control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy. HIV Med AIDS 2004;18:1347-9
27. Negredo E, Molto J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004;18:459-63
28. Sommadossi JP. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS 1998;12(Suppl 3):S1-8
29. IDA Price Indicator List, 2004
30. Gazzard B, DeJesus E, Campo R, , et al., (for the Study 934 Team). The Combination of Tenofovir (TDF), Emtricitabine (FTC) and Efavirenz (EFV) has significantly greater responses vs. fixed dose Zidovudine/Lamivudine (CBV) and EFV in antiretroviral naive patients: A 24 week preliminary analysis. 44th ICAAC. October 30-November 2 2004; Washington, DC. Abstract late breaker H-1137c
31. DeJesus E, Herrera G, Teofilo E, et al. Efficacy and safety of abacavir vs zidovudine in combination with efavirenz in the treatment of antiretroviral naïve adults with HIV-1 infection (Study CNA30024). 43rd ICAAC, September, 2003; Abstract H-1722b
32. Moyle G. The once-a-day era is upon us. AIDS Reader 2002;12:56-8
33. Duran S, Saves M, Spire B, , et al., APROCO Study Group. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2004;15:2441-4
34. Barbaro G. HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovasc Res 2003;60:87-95. (Review)
35. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005;191:1686-96; Epub 2005 Apr 12
36. Buffet M, Schwarzinger M, Amellal B, et al. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol 2005;33:60-4
37. Cherry CL, Lal L, Thompson KA, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2005;38:263-7
38. McComsey GA, Paulsen DM, Lonergan JT, et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005;19:15-23
39. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201
40. Powderly W, Cahn P, Raffi F, et al. Lipid abnormalities and body habitus in a double-blind, randomized, controlled trial comparing emtricitabine to stavudine in HIV+ ART-naive patients. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (11th CROI). February 8-11, 2004. San Francisco, CA; Abstract 717
41. Easterbrook P, Waters A, Murad S, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med 2003;4:321-4
42. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004;14:335-42
43. James JS. 1592 (abacavir): do not rechallenge after hypersensitivity reaction. AIDS Treat News 1997;(No. 285):1, 5
44. [www.fda.gov/]
45. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004;48:1469-87
46. Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001;15:1695-700
47. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study (902). AIDS 2002;16:1257-63
48. Squires K, Pozniak AL, Pierone Jr G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003;139:313-20
49. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 2004;37:1489-95
50. Mauss S, Berger F, Schmutz G, et al. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005;19:93-9
51. Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8; Epub 2005 Mar 17
52. Mauss S, Berger F, Schmutz G, et al. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005;19:93-5
53. Earle KE, Seneviratne T, Shaker J, et al. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004;19:714-21
54. ADHOC International Steering Committee. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med 2002;3:229-38
55. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63
56. Keiser P, Nassar N, White C, et al. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Triaks 2002;3:296-303
57. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002;185:1062-9; Epub 2002 Apr 1
58. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002;16:53-61
59. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005;19:463-71
60. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003;187:725-35; Epub 2003 Feb 24
61. Mofenson LM. Efavirenz reclassified as FDA pregnancy category D. AIDS Clin Care 2005;17:17
62. Hill JB, Sheffield JS, Zeeman GG, et al. Hepatotoxicity with antiretroviral treatment of pregnant women. Obstet Gynecol 2001;98:909-11
63. Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR 2001;49:1153-6
64. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, et al. Liver toxicity caused by nevirapine. AIDS 2002;16:290-1
65. Pineda JA, Macias J. Progression of liver fibrosis in patients co-infected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J Antimicrob Chemother 2005;55:417-19; Epub 2005 Feb 24
66. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr 2004;35:492-502
67. Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003;83:1-9
68. Scott JD. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. Am J Health Syst Pharm 2005;62:809-15
69. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-13
70. Barreiro P, Camino N, de Mendoza C, et al. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. Int J Antimicrob Agents 2002;20:438-43
71. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-46
72. DeJesus E, LaMarca A, Sension M, et al. The context study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003. Boston, MA, USA; Abstract 178
73. Gathe Jr JC, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18:1529-37
74. Nadler J, Rodriguez-French A, Millard J, et al. The NEAT study: GW433908 efficacy and safety in ART-naïve subjects, final 48-week analysis. 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003. Boston, MA, USA; Abstract 177
75. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 2003;188:635-42; Epub 2003 Aug 20
76. Youle M, Gerstoft J, Fox Z, et al. The final week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100mg bid) versus saquinavir/ritonavir (1000/100mg bid): The MaxCmin2 trial. Program and abstracts of the 9th European AIDS Conference (EACS), 1st EACS Resistance & Pharmacology Workshop, October 25-29, 2003, Warsaw, Poland; Abstract F11/3
77. MacManus S, Yates PJ, Elston RC, et al. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004;18:651-5
78. Badaro R, DeJesus E, Lazzarin A, et al. Efficacy and Safety of Atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combinbation with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16 week results from BMS AI424-045. 2nd IAS Conference on HIV Patogénesis and Traetment. July 13-16, 2003. Paris, France; Abstract 118
79. Sanne I, Piliero P, Squires K, , et al., AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18-29
80. Squires KE, Thiry A, Giordano M, et al. Atazanavir (ATV) QD and Efavirenz (EFV) AQ with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (AI424-034), 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 27-30, 2002, San Diego; Abstract H-1076
81. Miller V, Cozzi-Lepri A, Hertogs K, et al. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antivir Ther 2000;5:49-55
82. Montaner JSG, Harrigan R, Jahnke N, et al. Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001;15:61-9
83. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001;286:171-9
84. Gulick R, Ribaudo H, Shikuma C, et al. ACTG 5095: A comparative study of 3 protease inhibitor sparing antiretroviral regimens for the initial treatment of HIV infection Cornell, New York, USA, Harvard School of Public Health, Boston, USA. The 2nd IAS Conference on HIV Pathogenesis and Treatment, 2003 (Oral Abstract)
85. Katlama C, Fenske S, Gazzard B, et al. TRIZAL study: switching from successful HAART to Trizivir (abacavirlamivudine-zidovudine combination tablet): 48 weeks efficacy, x safety and adherence results. HIV Med 2003;4:79-86